Therapeutic use of agonist ligands specific to G2A receptor

Details Therapeutic use of agonist ligands specific to G2A receptor Therapeutic use of agonist ligands specific to G2A receptor

2003-03-25

2008-08-12

Marschel, Ardin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

Reexamination Certificate

active

07410955

ABSTRACT:
The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingophosphorylcholine) or derivatives thereof to the subject. The agonist ligands for G2A receptor according to the present invention and pharmaceutical- or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.

REFERENCES:
patent: 4746652 (1988-05-01), Buckalew et al.
patent: 6207412 (2001-03-01), Weng et al.
patent: WO 02/24222 (2002-03-01), None
patent: WO 02/092104 (2002-11-01), None
Riedermann et al. Anti-inflammatory strategies for the treatment of sepsis. Expert Opin. Biol. Ther. (2003) 3(2):339-350.
Rikitake et al. Expression of G2A, a Receptor for Lysophosphatidylcholine by Macrophages in Murine, Rabbit and Human Atherosclerotic Plaques. Arterioscler Thromb Vasc Biolo (2002) p. 2049-2053.
Falcone et al. Ascaris suum-Derived Products Induce Human Neutrophil Activation via a G Protein-Coupled Receptor that Interacts with the Interleukin-8 Receptor Pathway. Infection and Immunity (2001) vol. 69, No. 6 pp. 4007-4018.
Oxford English Dictionary Online© Oxford University Press (2007).
Yan et al. Therapeutic effects of lysophosphatidylcholine on experimental sepsis. Nature Medicine, 2004, vol. 10, No. 2, pp. 161-167.
Carson M, and Lo D, “The Push-Me Pull-You of T Cell Activation” (2001)Science293:618-619.
Kabarowski Jhs, et al., “Lysophosphatidylcholine as a Ligand for the Immunoregulatory Receptor G2A” (2001)Science293(5530):702-705.
Zhu K, et al., “Sphingosylphosphorylcholine and Lysophosphatidylcholine Are Ligands for the G Protein-coupled Receptor GPR4” (2001)J. Biol. Chem.276(44):41325-41335.
Heermeier K, et al., “Oxidized LDL Suppresses NF-κ1B and Overcomes Protection from Apoptosis in Activated Epithelial Cells” (2001)J. Am. Soc. Nephrol12:456-463.
Lu, Ql, et al., “Mice Lacking the Orphan G Protein-coupled Receptor G2A Develop a Late-Onset Autoimmune Syndrome” (2001)Immunity14:561-571.
Fukushima N, et al. “Lysophospholipid Receptors” (2001)Annu. Rev. Pharmacol. Toxicol.41:507-534.
Lynch Kr, et al., “Life on the Edg” (2001)Trends in Pharmacol. Sci.20(12):473-475.
Xu Y, et al., “Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1” (2000) Nat. Cell. Biol. 2(5):264-267.
Rikitake Y, et al., “Expression of G2A, a Receptor for Lysophosphatidylcholine, by Macrophages in Murine, Rabbit, and Human Atherosclerotic Plaques” (2002)Arterioscler Thromb Vasc Biol.22:2049-2053.

Affiliated with

Also associated with

Rating

Therapeutic use of agonist ligands specific to G2A receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic use of agonist ligands specific to G2A receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of agonist ligands specific to G2A receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4004038